Brief: Catalyst Pharmaceuticals Announces Settlement Of FIRDAPSE (Amifampridine) Patent Litigation With Teva Pharmaceuticals

Catalyst Pharmaceuticals

08/01/2025 17:33

Jan 8 (Reuters) - Catalyst Pharmaceuticals Inc  CPRX.O :
    * CATALYST PHARMACEUTICALS ANNOUNCES SETTLEMENT OF FIRDAPSE®
(AMIFAMPRIDINE) PATENT LITIGATION WITH TEVA PHARMACEUTICALS
    * CATALYST PHARMACEUTICALS: UNDER AGREEMENT, TEVA WILL NOT
MARKET
GENERIC VERSION OF FIRDAPSE IN U.S. EARLIER THAN FEB 25, 2035,
IF APPROVED BY U.S. FDA
    * CATALYST PHARMACEUTICALS INC - PENGING FIRDAPSE PATENT
LITIGATION AGAINST HETERO AND LUPIN ONGOING

Source text:  ID:nGNX4kY25S 
Further company coverage:  CPRX.O 

 ((Reuters.Briefs@thomsonreuters.com;))